PubRank

William Vainchenker

Author PubWeight™ 212.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 18.43
2 Mutation in TET2 in myeloid cancers. N Engl J Med 2009 16.07
3 TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011 5.28
4 JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 2006 3.37
5 Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013 3.10
6 Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2009 2.77
7 Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 2002 2.62
8 Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011 2.50
9 TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009 2.18
10 Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. Development 2002 2.16
11 A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood 2009 2.08
12 TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009 1.95
13 Apoptosis regulation in tetraploid cancer cells. EMBO J 2006 1.89
14 NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004 1.88
15 Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood 2011 1.87
16 Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood 2002 1.84
17 The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood 2007 1.83
18 Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004 1.79
19 JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008 1.77
20 JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem 2005 1.74
21 Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation. Blood 2010 1.73
22 Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006 1.71
23 MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood 2009 1.70
24 Clonal architecture of chronic myelomonocytic leukemias. Blood 2013 1.67
25 Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood 2007 1.66
26 Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood 2010 1.64
27 Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. Blood 2010 1.63
28 Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood 2008 1.61
29 Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood 2012 1.59
30 An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med 2009 1.58
31 Transfer of differentiation signal by membrane microvesicles harboring hedgehog morphogens. Blood 2006 1.58
32 Activating mutations in human acute megakaryoblastic leukemia. Blood 2008 1.56
33 Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood 2006 1.56
34 High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006 1.55
35 Ikaros inhibits megakaryopoiesis through functional interaction with GATA-1 and NOTCH signaling. Blood 2013 1.52
36 Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/- chimeric mice. Blood 2005 1.51
37 Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows. Haematologica 2007 1.51
38 An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood 2005 1.50
39 Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2006 1.50
40 Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 2009 1.47
41 Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004 1.46
42 Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002 1.45
43 Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 2007 1.44
44 The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest 2009 1.44
45 miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood 2010 1.41
46 Quantitative and qualitative in vitro analysis of the stem cell potential of hematopoietic cells purified from murine skeletal muscle. Cell Res 2007 1.40
47 Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood 2006 1.40
48 FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. J Clin Invest 2004 1.39
49 Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood 2011 1.37
50 Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2006 1.35
51 The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood 2008 1.28
52 Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood 2010 1.28
53 EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation. Blood 2008 1.28
54 The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 2007 1.27
55 Mechanisms of WASp-mediated hematologic and immunologic disease. Blood 2004 1.26
56 Differential regulation of actin stress fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes. Blood 2004 1.25
57 JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. Blood 2013 1.25
58 Intracellular localization and constitutive endocytosis of CXCR4 in human CD34+ hematopoietic progenitor cells. Stem Cells 2004 1.24
59 Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood 2005 1.23
60 RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. Nat Commun 2012 1.22
61 Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood 2006 1.21
62 BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006 1.21
63 Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 2005 1.20
64 Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat 2013 1.18
65 The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. Blood 2006 1.17
66 Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models. J Exp Med 2012 1.16
67 A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol 2010 1.14
68 Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. J Clin Invest 2014 1.13
69 Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood 2002 1.12
70 A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood 2007 1.12
71 Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells. Blood 2004 1.11
72 RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. Blood 2005 1.10
73 Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood 2007 1.10
74 P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. Blood 2008 1.09
75 Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood 2009 1.08
76 A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005 1.08
77 Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 2002 1.07
78 Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. Blood 2011 1.06
79 Microarray analysis of LIF/Stat3 transcriptional targets in embryonic stem cells. Stem Cells 2005 1.05
80 Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood 2009 1.05
81 A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. Blood 2003 1.04
82 STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 2013 1.04
83 Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood 2006 1.02
84 p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005 1.02
85 Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell 2005 1.01
86 Role for the nuclear factor kappaB pathway in transforming growth factor-beta1 production in idiopathic myelofibrosis: possible relationship with FK506 binding protein 51 overexpression. Cancer Res 2005 1.00
87 Effects of bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary hypertension in mice. Respir Res 2007 0.99
88 Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol 2005 0.99
89 Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood 2014 0.98
90 Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. Blood 2010 0.98
91 RNA interference shows critical requirement for NF-kappa B p50 in the production of IL-12 by human dendritic cells. J Immunol 2003 0.97
92 FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. Cancer Res 2011 0.96
93 Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood 2012 0.96
94 Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J 2011 0.95
95 A partial down-regulation of WASP is sufficient to inhibit podosome formation in dendritic cells. Mol Ther 2005 0.95
96 Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Exp Hematol 2003 0.95
97 Megakaryocyte polyploidization is associated with a functional gene amplification. Blood 2002 0.93
98 Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 2003 0.93
99 Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene 2003 0.92
100 Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 2004 0.92
101 MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. Blood 2012 0.92
102 Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 2002 0.92
103 LYL-1 deficiency induces a stress erythropoiesis. Exp Hematol 2011 0.91
104 Identification of CXCR4 as a new nitric oxide-regulated gene in human CD34+ cells. Stem Cells 2006 0.91
105 Notch/Delta4 interaction in human embryonic liver CD34+ CD38- cells: positive influence on BFU-E production and LTC-IC potential maintenance. Stem Cells 2005 0.90
106 Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. J Cell Mol Med 2013 0.90
107 Presence of a defect in karyokinesis during megakaryocyte endomitosis. Cell Cycle 2012 0.89
108 Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells. J Cell Sci 2002 0.88
109 Imatinib effect on growth and signal transduction in polycythemia vera. Exp Hematol 2007 0.87
110 A major role of TGF-beta1 in the homing capacities of murine hematopoietic stem cell/progenitors. Blood 2010 0.87
111 Generation and characterisation of Rhd and Rhag null mice. Br J Haematol 2009 0.87
112 Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients. Br J Haematol 2008 0.86
113 A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm. N Engl J Med 2015 0.86
114 Absence of mutations in the HoxA10, HoxA11 and HoxD11 nucleotide coding sequences in thrombocytopenia with absent radius syndrome. Br J Haematol 2002 0.85
115 Concomitant germ-line RUNX1 and acquired ASXL1 mutations in a T-cell acute lymphoblastic leukemia. Eur J Haematol 2013 0.85
116 Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant. Oncogene 2002 0.85
117 Applying ecological and evolutionary theory to cancer: a long and winding road. Evol Appl 2012 0.84
118 Distinct effects of the soluble versus membrane-bound forms of the notch ligand delta-4 on human CD34+CD38low cell expansion and differentiation. Stem Cells 2007 0.84
119 The transcription factor Srf regulates hematopoietic stem cell adhesion. Blood 2010 0.84
120 MplK, a natural variant of the thrombopoietin receptor with a truncated cytoplasmic domain, binds thrombopoietin but does not interfere with thrombopoietin-mediated cell growth. Exp Hematol 2002 0.83
121 Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development. Exp Hematol 2007 0.83
122 Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models. Best Pract Res Clin Haematol 2006 0.83
123 Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis. Blood 2010 0.83
124 Quantitative Oct4 overproduction in mouse embryonic stem cells results in prolonged mesoderm commitment during hematopoietic differentiation in vitro. Stem Cells 2006 0.82
125 Requirement for mitogen-activated protein kinase activation in the response of embryonic stem cell-derived hematopoietic cells to thrombopoietin in vitro. Blood 2002 0.82
126 Putative innate immunity of antiatherogenic paraoxanase-2 via STAT5 signal transduction in HIV-1 infection of hematopoietic TF-1 cells and in SCID-hu mice. J Stem Cells 2010 0.81
127 Recurrent V75M mutation within the Wiskott-Aldrich syndrome protein: description of a homozygous female patient. Eur J Haematol 2005 0.81
128 Differential signalling of NH2-terminal flag-labelled thrombopoietin receptor activated by TPO or anti-FLAG antibodies. Cell Signal 2004 0.81
129 Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity. J Biol Chem 2009 0.80
130 New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. Semin Thromb Hemost 2006 0.80
131 Fucoidan promotes early step of cardiac differentiation from human embryonic stem cells and long-term maintenance of beating areas. Tissue Eng Part A 2014 0.80
132 TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells. Stem Cells 2014 0.80
133 Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. Exp Hematol 2003 0.80
134 [Mutations in TET2 in myeloid cancers]. Med Sci (Paris) 2009 0.80
135 Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. PLoS One 2013 0.79
136 TET2, a tumor suppressor in hematological disorders. Biochim Biophys Acta 2012 0.79
137 Isolation and culture of megakaryocyte precursors. Methods Mol Biol 2004 0.79
138 Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin. J Immunol 2006 0.79
139 BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. Cell Signal 2008 0.78
140 Small-molecule inhibitors in myeloproliferative neoplasms: are we aiming for the right targets? Hematology Am Soc Hematol Educ Program 2012 0.78
141 Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. Clin Lymphoma Myeloma 2009 0.77
142 [A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera]. Med Sci (Paris) 2005 0.77
143 Evaluation of hematopoietic potential generated by transplantation of muscle-derived stem cells in mice. Stem Cells Dev 2004 0.77
144 [Fli1 haploinsufficiency underlies Paris-Trousseau thrombopenia]. Med Sci (Paris) 2004 0.77
145 Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor. Haematologica 2013 0.77
146 Ex vivo expansion marginally amplifies repopulating cells from baboon peripheral blood mobilized CD34+ cells. Br J Haematol 2002 0.76
147 Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. J Clin Invest 2017 0.75
148 Thrombopoietin responsiveness reflects the number of doublings undergone by megakaryocyte progenitors. Blood 2004 0.75
149 [Megakaryopoiesis: regulation of platelet production by thrombopoietin]. Bull Acad Natl Med 2013 0.75
150 [From giant to micro: a platelet story]. Med Sci (Paris) 2008 0.75
151 [In cauda venenum or the importance of TET(2)]. Med Sci (Paris) 2011 0.75
152 Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors. Int J Cancer 2007 0.75